Document Detail


Factor XIII Val34Leu polymorphism as a modulator of fibrin clot permeability and resistance to lysis in patients with severe coronary artery disease.
MedLine Citation:
PMID:  19784898     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: A common G to T transition in codon 34 with the subsequent valine with leucine replacement in the factor (F) XIII A-subunit affects fibrin formation and stabilisation in vitro. Data on the effects of Leu34 allele on cardiovascular thromboembolic events in vivo are conflicting. AIM: We investigated whether FXIII Val34Leu polymorphism is potent enough to affect fibrin clot properties in patients with advanced coronary artery disease (CAD). METHODS: We studied 113 patients, aged 62.8 +/- 6.1 years, who were scheduled for elective isolated coronary artery bypass grafting surgery (CABG). Patients were compared with 98 healthy age-matched controls. Ex vivo fibrin clot permeability and lysis time (t5oo/o) were determined in citrated plasma. RESULTS: Patients scheduled for CABG had lower clot permeability (9.14 + 1.64 vs. 10.02 + 1.12 x 10(-9) cm2; p = 0.0002) and longer t50%, (8.45 +/- 1.94 vs. 7.63 +/- 1.24 min; p < 0.0001) than controls. The Leu34 carriers, i.e. 9 (8%) Leu34Leu homozygous and 23 (20%) Val34Leu heterozygous subjects, had lower permeability by 23% in the CAD group compared with 81 (72%) patients with Val34Val genotype. A similar intergroup difference was observed for t50%, which was longer in Leu34 carriers (p < 0.0001). The FXIII Leu34 allele frequency in the control group was similar as well as the impact of Leu34 allele on fibrin properties. The effect of FXIII Leu34 allele on permeability and t50%, was not affected by homocysteine, C-reactive protein and fibrinogen levels in CAD patients and controls. CONCLUSIONS: Like in healthy subjects, in patients scheduled for CABG, the FXIII Leu34 allele is associated with decreased fibrin clot permeability and efficiency of lysis.
Authors:
Ewa Stepień; Dariusz Plicner; Bogusław Kapelak; Ewa Wypasek; Jerzy Sadowski; Anetta Undas
Related Documents :
22151748 - Predictive factors for cholangiocarcinoma associated with hepatolithiasis determined on...
11693278 - The incidence of coronary artery disease in patients with symptomatic bradyarrhythmias.
18607248 - Normal or near normal myocardial perfusion stress imaging in patients with severe coron...
15547648 - Classic intermittent claudication is an uncommon manifestation of lower extremity perip...
24765608 - Arterial stiffness and functional outcome in acute ischemic stroke.
23530728 - Transepidermal water loss in erythrodermic patients of various aetiologies.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Kardiologia polska     Volume:  67     ISSN:  0022-9032     ISO Abbreviation:  Kardiol Pol     Publication Date:  2009 Aug 
Date Detail:
Created Date:  2009-12-29     Completed Date:  2010-07-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0376352     Medline TA:  Kardiol Pol     Country:  Poland    
Other Details:
Languages:  eng     Pagination:  947-55     Citation Subset:  IM    
Affiliation:
Department of Cardiac Surgery, Anesthesiology and Experimental Cardiology, Institute of Cardiology, Jagiellonian University Collegium Medicum, Krakow, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
C-Reactive Protein / metabolism
Case-Control Studies
Coronary Artery Bypass
Coronary Artery Disease / blood,  genetics*,  surgery
Factor XIII / genetics*
Female
Fibrin / genetics*,  metabolism
Fibrinolysis / genetics*
Homocysteine / blood
Humans
Male
Middle Aged
Permeability
Polymorphism, Genetic*
Risk Assessment
Chemical
Reg. No./Substance:
454-28-4/Homocysteine; 9001-31-4/Fibrin; 9007-41-4/C-Reactive Protein; 9013-56-3/Factor XIII

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  POL-TAVI First - Polish report on transcatheter aortic valve implantation (TAVI) of Edwards-Sapien p...
Next Document:  Sutureless aortic valve bioprothesis '3F/ATS Enable' - 4.5 years of a single-centre experience.